ARA-290 vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- ARA-290 has stronger research evidence (Phase II/III Trials) compared to PE-22-28 (Animal Studies).
Detailed Comparison
| Attribute | ARA-290 | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | 4 mg daily Once daily | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Subcutaneous injection | Intranasal or subcutaneous injection |
| Typical Duration | 28-day courses in trials | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Consistent daily timing | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: ARA-290 vs PE-22-28
What is the difference between ARA-290 and PE-22-28?
ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.